Accueil › Myélome multiple › Californie › San Francisco
Essais cliniques pour Myélome multiple à San Francisco, CA
15 études pour Myélome multiple recherchent des participants dans et autour de San Francisco (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Recrutement en coursPhase 1
- University of California San Francisco, San Francisco
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- University of California San Francisco, San Francisco
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Recrutement en coursPhase 2
- University of California San Francisco, San Francisco
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Recrutement en coursPhase 2
- University of California San Francisco, San Francisco
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Recrutement en coursPhase 4
- University of California San Francisco, San Francisco
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1/2
- UCSF, San Francisco
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- Kaiser Permanente - South San Francisco Medical Center, San Francisco
- California Pacific Medical Center Research Institute, San Francisco
- Kaiser Permanente - San Francisco Medical Center, San Francisco
- et 1 autres
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Recrutement en coursPhase 1
- University of California, San Francisco, San Francisco
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 2
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- UCSF, San Francisco
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Recrutement en coursPhase 1
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Recrutement en coursPhase 1/2
- Research Site, San Francisco
Delayed Toxicities Post-CAR-T
Recrutement en coursÉtude observationnelle
- UCSF Medical Center, San Francisco
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 1
- University of Calfornia, San Francisco, San Francisco
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO26 études
- Columbus, OH24 études
- Rochester, MN24 études
- Baldwin Park, CA23 études
- St. Louis, MO23 études
- Chicago, IL22 études
Autres études à San Francisco
- Cancer de la prostate45 études
- Cancer du sein43 études
- Cancer du poumon non à petites cellules37 études
- Cancer (tous types)35 études
- Insuffisance cardiaque29 études
- Cancer métastatique29 études
- Cancer du poumon23 études
- Mélanome22 études
- Cancer du pancréas20 études
- Cancer colorectal19 études
- Maladie cardiovasculaire18 études
- Glioblastome18 études
Source : ClinicalTrials.gov, données récupérées le 1 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.